News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bayer AG (BAY.F) Says Blood Thinner Cuts Risk of Repeat Heart Attack


8/29/2012 7:36:46 AM

Bayer said results from a late-stage clinical trial showed its anti-clotting pill Xarelto cut the risk of recurrence in patients who have suffered a severe heart attack, as it strives to secure U.S. approval for wider use of the drug. Results from the trial showed that adding Xarelto to standard therapy - typically aspirin and Sanofi's Plavix - significantly reduced cardiovascular death, heart attack or stroke compared with standard therapy alone. The results came from the analysis of a sub-group of patients in a wider drug trial that tested the blood clot preventer on patients with acute coronary syndrome (ACS).

Read at Reuters
Read at BusinessWeek
Read at Fox News
Read at News Release


comments powered by Disqus
Bayer AG
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES